Valeant Pharmaceuticals Intl Company Profile (NYSE:BVF)

About Valeant Pharmaceuticals Intl (NYSE:BVF)

Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:BVF
  • CUSIP: N/A
  • Web: www.valeant.com/
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: -1.66%
  • Return on Equity: -3.90%
  • Return on Assets: -0.35%
 

Frequently Asked Questions for Valeant Pharmaceuticals Intl (NYSE:BVF)

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the New York Stock Exchange (NYSE) under the ticker symbol "BVF."

Who are some of Valeant Pharmaceuticals Intl's key competitors?

Who are Valeant Pharmaceuticals Intl's key executives?

Valeant Pharmaceuticals Intl's management team includes the folowing people:

  • Joseph C. Papa, Chairman of the Board, Chief Executive Officer
  • Paul S. Herendeen, Chief Financial Officer, Executive Vice President
  • Christina Ackermann, Executive Vice President, General Counsel
  • Thomas J. Appio, Executive Vice President, Company Group Chairman, International
  • William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology
  • Thomas W. Ross Sr, Lead Independent Director
  • Richard U. DeSchutter, Independent Director
  • Fredric N. Eshelman Pharm.D., Ph.D., Independent Director
  • D. Robert Hale, Independent Director
  • Argeris N. Karabelas Ph.D., Independent Director

How do I buy Valeant Pharmaceuticals Intl stock?

Shares of Valeant Pharmaceuticals Intl can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.


MarketBeat Community Rating for Valeant Pharmaceuticals Intl (NYSE BVF)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  115
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals Intl (NYSE:BVF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Valeant Pharmaceuticals Intl (NYSE:BVF)
Price Target History for Valeant Pharmaceuticals Intl (NYSE:BVF)
Analysts' Ratings History for Valeant Pharmaceuticals Intl (NYSE:BVF)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Valeant Pharmaceuticals Intl (NYSE:BVF)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Valeant Pharmaceuticals Intl (NYSE:BVF)
Latest Headlines for Valeant Pharmaceuticals Intl (NYSE:BVF)
Source:
DateHeadline
investorplace.com logoHow to Approach Valeant Pharmaceuticals Intl Inc (VRX) Stock With Reason
investorplace.com - October 5 at 10:58 AM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Is Set for Near-100% Return
investorplace.com - October 3 at 11:35 AM
finance.yahoo.com logoValeant Announces Pricing Of Private Offering Of Senior Secured Notes
finance.yahoo.com - October 3 at 12:47 AM
bloomberg.com logoValeant Digs Into Its Leverage Spiral
www.bloomberg.com - October 2 at 7:41 PM
finance.yahoo.com logoWhy Valeant Stock (VRX) Can’t Survive the Coming Correction
finance.yahoo.com - October 2 at 7:41 PM
seekingalpha.com logoValeant: Paying Its Debts
seekingalpha.com - October 2 at 7:41 PM
News IconBRIEF-Valeant Pharmaceuticals completes sale of Inova Pharmaceuticals
www.businessinsider.com - September 29 at 3:58 PM
nasdaq.com logoValeant Closes Sale Of INova Pharma To Pacific Equity Partners And Carlyle Group
www.nasdaq.com - September 29 at 8:34 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: PTC Therapeutics and Valeant Pharmaceuticals
finance.yahoo.com - September 29 at 8:34 AM
barrons.com logoUPDATE: Why Valeant is Sinking
www.barrons.com - September 29 at 8:34 AM
marketwatch.com logoValeant Pharmaceuticals Completes Sale Of iNova Pharmaceuticals To Pacific Equity Partners And The Carlyle Group
www.marketwatch.com - September 29 at 8:33 AM
marketwatch.com logoValeant to Participate at the Deutsche Bank 25th Annual Leveraged Finance Conference
www.marketwatch.com - September 27 at 10:45 PM
fool.ca logoValeant Pharmaceuticals Intl Inc.: Value Trap or Opportunity?
www.fool.ca - September 27 at 10:45 PM
prnewswire.com logoValeant Pharmaceuticals Provides Update On Canadian Regulatory Filing About Future Financing Plans
www.prnewswire.com - September 27 at 10:45 PM
theglobeandmail.com logoHow Valeant’s financial reporting may still echo the bad old days
www.theglobeandmail.com - September 25 at 7:56 PM
nasdaq.com logoShould Value Investors Consider Valeant Pharmaceuticals International (VRX) Stock?
www.nasdaq.com - September 21 at 11:24 AM
feeds.benzinga.com logoWhat You Should Know About The Drug Approval Valeant Could Receive This Week
feeds.benzinga.com - September 18 at 11:19 AM
nasdaq.com logoChou RRSP Fund Buys Valeant Pharmaceuticals International Inc, EXCO Resources Inc, Sells ...
www.nasdaq.com - September 13 at 5:59 PM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Is STILL Too Ugly to Buy
investorplace.com - September 12 at 9:20 AM
bizjournals.com logoQuébec Superior Court Grants Leave under Québec Securities Act in Valeant Pharmaceuticals Securities Class Action
www.bizjournals.com - September 6 at 4:49 PM
fool.ca logo4 Reasons Valeant Pharmaceuticals Intl Inc. Might Be a Good Investment Today
www.fool.ca - September 6 at 4:49 PM
zacks.com logoValeant (VRX) Continues to Lose Ground: Can It Bounce Back?
www.zacks.com - September 2 at 3:09 AM
globenewswire.com logoProgenics Pharmaceuticals Presents Data from AZEDRA® Pivotal Phase 2b Study at the 5th International Symposium on Pheochromocytoma and Paraganglioma
globenewswire.com - August 31 at 4:42 PM
benzinga.com logoThere's No Fundamental Reason For Valeant Shares To Be Down
www.benzinga.com - August 30 at 6:08 PM
nasdaq.com logoValeant Pharmaceuticals International Becomes Oversold (VRX)
www.nasdaq.com - August 29 at 5:12 PM
investorplace.com logoWhy Finish Line Inc (FINL), Valeant Pharmaceuticals Intl Inc (VRX) and Best Buy Co Inc (BBY) Are 3 of Today’s Worst Stocks
investorplace.com - August 29 at 4:45 PM
theglobeandmail.com logoValeant faces potentially costly securities fraud lawsuit in U.S.
www.theglobeandmail.com - August 25 at 6:34 PM
investorplace.com logoWhy Ulta Beauty Inc (ULTA), Valeant Pharmaceuticals Intl Inc (VRX) and GameStop Corp. (GME) Are 3 of Today’s Worst Stocks
investorplace.com - August 25 at 4:53 PM
feeds.benzinga.com logoWhat's The FDA Saying About Valeant's Manufacturing Facility Issues?
feeds.benzinga.com - August 21 at 10:21 AM
fool.ca logoWhy an Investment in Valeant Pharmaceuticals Intl Inc. Needs to Be Long Term
www.fool.ca - August 18 at 4:56 PM
seekingalpha.com logoValeant Pharmaceuticals International, Inc. 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 18 at 4:56 PM
rttnews.com logoValeant Receives FDA Confirmation Of VAI Inspection For Tampa Facility
www.rttnews.com - August 17 at 11:12 PM
benzinga.com logoValeant's CEO Details The Company's 'Great Progress' And What's Next
www.benzinga.com - August 17 at 6:09 PM
247wallst.com logoValeant Pharmaceuticals Gets Boost From FDA Update
247wallst.com - August 17 at 6:09 PM
fool.ca logoValeant Pharmaceuticals Intl Inc.: Still a Risk or on the Way up?
www.fool.ca - August 17 at 6:09 PM
marketwatch.com logoValeant Pharma works to resolve FDA concerns at Tampa plant
www.marketwatch.com - August 17 at 3:23 AM
marketwatch.com logoValeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility
www.marketwatch.com - August 16 at 10:21 PM
investorplace.com logoThe Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak
investorplace.com - August 16 at 10:32 AM
fool.ca logoHow Rising Rates May Bankrupt Valeant Pharmaceuticals Intl Inc.
www.fool.ca - August 14 at 10:18 PM
marketwatch.com logoPaulson & Co., Inc. Reiterates Confidence In Valeant Strategy
www.marketwatch.com - August 9 at 10:00 PM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Scores 2 Vital Victories
investorplace.com - August 8 at 11:00 AM
investorplace.com logoTuesday’s Vital Data: Apple Inc. (AAPL), Alibaba Group Holding Ltd (BABA) and Valeant Pharmaceuticals Intl Inc (VRX)
investorplace.com - August 8 at 9:58 AM
prnewswire.com logoValeant Pharmaceuticals Receives Complete Response Letter from the FDA for ...
www.prnewswire.com - August 7 at 5:17 PM
investorplace.com logoHow Valeant Pharmaceuticals Intl Inc (VRX) Stock Can Make a Comeback
investorplace.com - August 7 at 10:00 AM
nasdaq.com logo3 Things You'll Want to Watch in Valeant Pharmaceuticals' Q2 Results
www.nasdaq.com - August 6 at 4:13 PM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock: Stupid Is as Stupid Does
investorplace.com - August 4 at 2:30 PM
investorplace.com logo3 Big Stock Charts for Friday: GoPro Inc (GPRO), Valeant Pharmaceuticals Intl Inc (VRX) and Microchip Technology Inc. (MCHP)
investorplace.com - August 4 at 1:53 PM
investorplace.com logoShould You Buy Valeant Pharmaceuticals Intl Inc (VRX) Stock? 3 Pros, 3 Cons
investorplace.com - July 24 at 1:16 PM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Is Back From the Abyss
investorplace.com - July 21 at 10:05 AM
fool.ca logoValeant Pharmaceuticals Intl Inc.: Is it Comeback Time?
www.fool.ca - July 20 at 6:32 PM

Social

Chart

Valeant Pharmaceuticals Intl (BVF) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.